T he modern armamentarium of anti-inflammatory therapies for IBD has improved the natural history of Crohn's disease (CD), especially when used before the development of extensive irreversible intestinal damage. However, stricturing complications represent the cumulative result of ongoing damage and are a major reason for surgery, disability, and reduced quality of life. 1 Although evidence is mounting that some strictures may be sufficiently responsive to medical management, many eventually cause obstructive symptoms that require surgery. 2, 3 Although surgical resection of strictured intestinal segments is often needed, such surgeries are not curative. Stricturing disease often recurs, and there are no current therapies that reverse existing fibrostenotic disease. 4 Although stricturoplasty and other bowel sparing techniques are being used more frequently, there remains a continued need to find alternatives to surgery whenever possible. 5 Endoscopic balloon dilation (EBD) has been shown to durably delay or prevent surgery in patients with stricturing CD. 6 The application of radial force to the fibromuscular components of intestinal strictures stretches and partially fractures the stenosis, relieving obstructive symptoms that otherwise would require surgery. 7 Most patients report immediate improvement in symptoms after EBD. The symptomatic benefits of EBD can be sustained, with the ability to avoid surgery at 1, 3, and 5 years in 80%, 57%, and 52%, respectively, of patients based on retrospective series. 8 Balloon dilation does present a risk of perforation and bleeding. The incidence of these serious adverse events has been reported to be 5.1% per dilation, and up to 8.7% when assessed by a patient after EBD. 9 Although EBD in CD is effective and reasonably safe, key factors predicting the likelihood of successfully avoiding surgery after dilation remain unclear. The ability to pass the endoscope, stricture overall length of less than 4 cm, and the absence of ulceration within the stricture channel have been associated with Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
Received for publication January 14, 2017; Accepted April 24, 2017. From the Departments of *Internal Medicine, and the avoidance of surgery after EBD. 10, 11 There is remaining debate as to whether stricture type, anastomotic versus de novo, smoking status, C-reactive protein (CRP), or stricture location affect the response to EBD. 9, 12 In addition, practitioners vary in both the selection of patients offered EBD and the endoscopic dilation technique itself. To address this knowledge gap, our aim was to determine how clinical, laboratory, and technical endoscopic dilation factors, specifically EBD sizes, were associated with avoidance or delay of surgery.
METHODS

Selection Criteria
This retrospective study was approved by the University of Michigan Institutional Review Board. Adult patients (age .18) with CD who underwent EBD between 2006 and 2014 at the University of Michigan Health System were identified using electronic medical records. CD diagnosis was determined by an outpatient International Classification of Diseases, Ninth Revision (ICD-9) code of 555.X plus one IBD medication in 2 separate encounters with confirmation by manual review of medical records. 13 In efforts to maintain some degree of stricture and EBD homogeneity, selection criteria included strictures within reach of a standard colonoscope in the distal ileum, ileocecal region, or colon. Both anastomotic and de novo intestinal strictures were included. Because of variation in the management and symptoms of various stricture types, patients with malignant, pouch-related, anorectal, ostomy-related, duodenal or jejunal, or strictures requiring deep enteroscopy with a balloon-endoscope were excluded from the analysis.
Clinical Data Collection
Electronic medical records were reviewed using a combination of automated data extraction (University of Michigan Data Warehouse Service), information retrieval search engines (EMERSE), and manual chart review. 14 Patient demographics, disease phenotype, surgical history, and medication use history at the time of dilation were extracted. Laboratory data closest to and before the index EBD were collected and included CRP, albumin, white blood cell and platelet counts, and hemoglobin. Computed tomography and magnetic resonance enterography studies performed within 4 months before dilation (where available) were reviewed by a single radiologist, masked to medical records and outcome, with extraction of maximum bowel wall thickness, stricture length, maximum bowel diameter upstream of structuring disease, and disease activity features of mural hyperenhancement and vascularity. When multiple strictures were present, features from stricture associated with either upstream dilation or the greatest bowel wall thickness were selected. Stricture dilation features were extracted from endoscopic records. Stricture type (de novo versus anastomotic), intestinal location of the stricture, minimum and maximum balloon size used for dilation, and ability to pass the endoscope after dilation were recorded. Maximum balloon dilation sizes were categorized based on quartiles and typical balloon stage sizes of ,14 mm, 14 to 15 mm, 16 to 18 mm, and .18 mm. When multiple strictures were present in the same intestinal segment, the stricture dilated to the smallest maximum caliber was used.
Primary Outcome Assessment
The primary outcome in this study was the occurrence of surgical resection of intestine after EBD. Surgical interventions included bowel resection, diverting ileostomy, and surgical stricturoplasty. Fistulotomies, ostomy revisions, and non-CDrelated surgeries (e.g., hernia repair and cholecystectomy) were not included. The time (d) from index EBD to surgery was measured in all patients who underwent surgery. Manual chart review, augmented by medical record search engine techniques (EMERSE), was used to capture the small portion of surgical events occurring outside the institution.
Statistical Analysis
All analyses considered a P-value of #0.05 as statistically significant and were conducted using SAS 9.4 (Cary, NC). Demographic, clinical, endoscopic dilation, and imaging features (where available) at the index dilation were compared between patients who avoided or underwent surgery during the follow-up period. Bivariate analysis using Cox proportional hazards regression models was used, comparing each individual predictor to the time until surgical intestinal resection. Kaplan-Meier curves of surgery-free survival, stratified by maximum size balloon dilation achieved, were produced using the LifeTable method. Multivariate Cox proportional hazards regression model building used a backward variable selection process with forced inclusion of age, sex, and other covariates deemed clinically relevant a priori. Continuous variables were also explored as categorical variables (with and without ordinal features) to provide the best model fit. Analysis of maximum likelihood estimates provided hazard ratios (HRs) and confidence limits (CLs) for each parameter within the model.
Ethical Considerations
The study protocol for data collection and storage was reviewed and approved by the University of Michigan Institutional Review Board.
RESULTS
Patient Characteristics
A total of 210 patients with a verified diagnosis of CD underwent EBD during the retrospective study period (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Of the identified subjects, exclusions were 24 patients for pouch-related dilation, 21 for anorectal strictures, 17 for ostomy-outlet dilation, 7 for requiring deep enteroscopy, 5 for proximal tract CD, and 1 patient was excluded for malignancyrelated dilation. The remaining 135 patients underwent a total of 292 endoscopic procedures with EBD over a mean follow-up time of 41.7 months (range 26.1-81.3 mo) among those avoiding surgery. Among all subjects, 38 (28.1%) underwent surgery with a median time to surgery of 14.7 (range 0.0-69.4) months. There was a nonsignificant trend of those undergoing surgery being younger compared with surgery avoiders (40.7 versus 45.9 yr, P ¼ 0.086). Otherwise, there were no significant differences in sex, disease duration, disease location, or history of fistulizing disease between those undergoing and avoiding surgery on bivariate analysis (Table 1 ). Regardless of whether EBD patients underwent or avoided surgery, most had a history of previous bowel resection before index EBD (72.2% versus 63.2%, P ¼ 0.311). Examining medication use at index dilation, most of them undergoing or avoiding surgery were using an anti-tumor necrosis factor (TNF) agent (50.0% versus 64.9%, P ¼ 0.200) with 13.2% and 26.8% using combination therapy, respectively (P ¼ 0.090). A single complication immediately after EBD was reported (0.34% by dilation, 0.74% by patient) with perforation at an ileocolonic de novo stricture dilated to a maximum diameter of 18 mm; the patient underwent urgent bowel resection.
Stricture Characteristics
Of all strictures, 38.5% were anastomotic and 38.5% were ileocolonic, involving the ileocecal valve or a continuous segment of the ileum and colon. There were no significant differences in stricture type (P ¼ 0.324) between those undergoing and avoiding surgery on bivariate analysis (Table 2) . Stricture location was not associated with the risk of surgery on bivariate analysis (P ¼ 0.593). Those failing to achieve a maximum bowel dilation of 14 mm or more were at increased risk of surgery (HR 3.53, 95% CL, 1.71-7.29). Compared with dilations less than 14 mm, those achieving maximum dilations of 14 to 15 mm (HR 0.31, 95% CL, 0.12-0.76) and 16 to 18 mm (HR 0.268, 95% CL, 0.12-0.63) exhibited a significant reduction in the risk of future surgery (Fig. 1) . There was no incremental reduction of risk for surgery between maximum dilation achieved of 14 to 15 mm compared with 16 to 18 mm (HR 0.88, 95% CL, 0.33-2.37). Interestingly, relative to maximum dilations of 14 to 18 mm, those dilated to .18 mm were at greater risk of surgery (HR 2.75, 95% CL, 1.18-6.43). Minimal balloon size used for EBD was not associated with the risk of eventual surgery (HR 0.928, 95% CL, 0.70-1.23).
Strictures unable to ever be traversed by a colonoscope across all dilation sessions (21, 15.6%) were associated with an increased hazard of surgery (HR 2.15, 95% CL, 1.01-4.54). However, the ability to traverse a stricture at the index dilation did not reduce the risk of future surgery (HR 1.62, 95% CL, 0.83-3.17). In those undergoing surgery, 71.1% underwent 1 dilation, 23.7% underwent 2, and 5.3% underwent 3 or more dilations before surgery with a mean time of 141 6 344 days from index dilation to surgery.
Of those avoiding surgery, 61.9% achieved maximum dilation at the index dilation, 25.8% required 2 dilations, and 12.4% required 3 or more endoscopic procedures to reach maximum dilation achieved. A mean time of 229 days (SD 265) was required to reach maximum dilation achieved among those avoiding surgery. Of those undergoing another dilation before either surgery or end of follow-up, those dilated to a maximum of 14 to 15 mm underwent subsequent maintenance dilation sooner than those achieving 16 to 18 mm (mean 240 6 137 versus 456 6 357 d, respectively, P ¼ 0.023). On subanalysis of anastomotic strictures, 12/52 (23.1%) patients had eventual revision surgery after a median of 388 days (range 14-1290 d) after index dilation. Similar to de novo strictures, anastomotic 
Laboratory and Imaging Predictors of Dilation Success
On bivariate analysis, the mean CRP value at index dilation was greater in those undergoing surgery (1.1 mg/dL) compared with those avoiding surgery (0.61 mg/dL, P ¼ 0.015). A CRP value above 1.5 mg/dL (occurring in 44 [32.6%] of the entire cohort) was associated with an increased hazard of eventual surgery (HR 2.64, 95% CL, 1.28-5.44, P ¼ 0.009). Other laboratory values within 3 months of index dilation, including hemoglobin, white blood cell and platelet counts, and albumin, did not differ between those undergoing and avoiding surgery (see Supplemental Table 1 , Supplemental Digital Content, http://links.lww.com/ IBD/B546). Despite our expectation, only 78 subjects (57.8%) had cross-sectional imaging within 4 months of index dilation. Analysis of partial imaging data demonstrated no significant difference between radiographic features of those undergoing and avoiding surgery. Considering the small sample size, we elected not to impute missing data, and partial imaging data were not included in the multivariate analysis.
Multivariate Model for Predicting Dilation Success
Surgical outcomes were modeled using Cox proportional hazard regression, adjusting for potential covariates; the most parsimonious model (based on the Akaike information criterion) is presented (Table 3) . On adjusted analysis, a maximum balloon dilation size of 14 to 18 mm was associated with a reduction in the hazard of surgery by over half compared with those reaching less than 14 mm (HR 0.31, 95% CL, 0.12-0.79, P ¼ 0.014). Presented alternatively, compared with those achieving 14 to 18 mm, a maximum dilation of less than 14 mm conferred an increased hazard of surgery (HR 2.88, 95% CL, 1.10-7.53, P ¼ 0.030). Again, dilation greater than 18 mm was associated with increased risk of surgery compared with a 14-to 18-mm dilation maximum size (HR 4.13, 95% CL, 1.45-11.76). There was no incremental reduction in the risk of surgery for those dilated to 16 to 18 mm compared with those only reaching 14 to 15 mm (HR 1.061, 95% CL, 0.33-3.41, P ¼ 0.920).
The initiation of anti-TNF therapy after EBD was associated with an increased hazard of surgery (HR 2.39, 95% CL, 1.09-5.25, P ¼ 0.029). Anti-TNF use at the time of dilation exhibited a nonsignificant trend of increased hazard of surgery (HR 3.77, 95% CL, 0.59-25.14, P ¼ 0.270). A CRP of 1.5 mg/dL was also associated with an increased hazard of FIGURE 1. Risk of surgery by maximum balloon dilation size achieved. Unadjusted Kaplan-Meier analysis stratifying patients by maximum balloon dilation size achieved. Patients achieving a maximum dilation of .14 mm were less likely to undergo surgery compared with smaller dilation sizes (P ¼ 0.014). There was no further reduction of future surgery in those dilated to 16 to 18 mm compared with 14 to 15 mm (P ¼ 0.618); however, the time between maintenance dilations was longer in those reaching 16 to 18 mm (456 6 357.3 versus 240 6 136.7 days, respectively, P ¼ 0.023).
surgery (HR 2.60, 95% CL, 1.12-5.94, P ¼ 0.027). Although stricture location (P ¼ 0.657) and anastomotic versus de novo stricture type (P ¼ 0.292) were not associated with surgical risk, both significantly contributed to model fit. Projected probabilities of future surgery in high-risk (anti-TNF use and CRP .1.5 mg/dL) and low-risk patients (no anti-TNF use and CRP ,1.5 mg/dL) are stratified by maximum balloon dilation size in Figure 2 . Age, sex, smoking, previous surgery or fistulizing disease, immunomodulator use before and after dilation, other laboratory data, and passage of the endoscope at index dilation were not significant and did not meaningfully influence the model.
DISCUSSION
Although the efficacy and safety of EBD have been described in previous retrospective analyses, best technical practices for EBD remain unclear. This study aids in addressing the knowledge gap of how the balloon size used affects effectiveness and durability of EBD, specifically in regard to avoiding surgery. We expected an approximate linear reduction in surgery-free survival with increasing maximum balloon diameter. Our finding of 14 mm as the threshold needed to avoid surgery was unexpectedly small. However, frequent dilation is impractical and potentially exposes patients to more risk of severe adverse events. The greater interval between maintenance EBD achieved with 16 to 18 mm compared with 14 to 15 mm maximum dilation sizes (456 versus 240 d, P ¼ 0.023) had a similar efficacy without a detectable increase in complications. Paradoxically, we found patients undergoing dilations .18 mm to be at increased risk of surgery compared with 14 to 18 mm maximum dilation sizes. Reviewing the clinical history of each patient, 15/17 (88.2%) previously underwent EBD to 16 to 18 mm. Of those undergoing surgery, 7/8 had a partial, but short lived, clinical response to 16 to 18 mm EBD and were subsequently dilated to 20 mm in efforts to relieve symptoms attributed to obstruction. We hypothesize that these patients' persistent symptoms, resulting in the decision for surgery, may have been less related to mechanical obstruction and instead the result of refractory disease activity.
Overall, these results are in agreement with a recent large pooled analysis in 1463 patients, which demonstrated that larger Elevated CRP levels and the use of anti-TNF in the setting of existing obstructive symptoms prompting stricture balloon dilation were identified as additional risk factors predicting future surgery. Using the multivariate Cox regression model, surgery-free survival is projected in high-risk (solid lines) and low-risk (dash lines) groups, stratified by maximum achieved balloon dilator size for 2 years after index dilation.
balloon sizes appear associated with lower probabilities of recurrent dilation. 15 In contrast to our findings, Bettenworth et al found only stricture length, not maximum dilation caliber, to be associated with the future risk of surgery. The analysis presented in this study adjusts for anti-TNF use history, inflammatory biomarkers, and did not include proximal gastrointestinal strictures, which may account for the discrepancy with the results of Butterworth and colleagues. In addition, in the Bettenworth study, the minimum dilation size reported was 15 mm, whereas nearly 25% of dilations in our study were less then 14 mm owing to difference in technical EBD practice patterns. Although increasing dilation caliber appears to reduce the probability of future surgery, some endoscopists may hesitate to perform larger dilations because of concerns for increasing risk of complications. Other studies have reported that balloon sizes of 20 mm or more are associated with major complications. 8, 10 In the Bettenworth et al pooled analysis, 11 EBD-related complications were reported in 1463 patients undergoing 3213 individual dilations. Despite using balloon sizes from 15 to 25 mm, there was no association found between dilation caliber and complications. 15 The low adverse event count within our cohort makes meaningful risk assessment difficult. What remains unclear is whether all strictures can tolerate the same degree of dilation in a single episode, or instead, if features exist to stratify the dilation capacity of individual stenoses. The presented data and existing literature suggest that the potentially the best balance of optimal dilation may be in the 16-to 20-mm range.
We did not find stricture type (anastomotic versus de novo) associated with surgery-free survival after EBD, which is in agreement with other studies. 8, 11, 15 We also found no difference between EBD success by stricture location across ileum, ileocolonic, or isolated colonic disease. Thienpont et al 9 found no association between CRP or medical treatment and surgery-free survival. In contrast to their findings, we found a CRP of .1.5 mg/dL and anti-TNF initiation after dilation to be risk factors for future surgery in the multivariate analysis. Potentially, the adjustment for maximum dilation size achieved, differences in dilation technique, and separation of existing anti-TNF use from initiation of anti-TNF after EBD explain the difference between these results. We found no association between albumin and other laboratory variables with EBD success. In addition, we did not find the ability to pass the endoscope through the stricture at the index dilation to be predictive of future avoidance of surgery. Although cautious to draw conclusions regarding the significance of minimal balloon size used, the data also suggest that a small initial stricture aperture should not deter providers from considering EBD.
Attempts to halt fibrostenotic disease progression is the goal of medication intensification, which commonly occurs in response to recognition of complicated CD. Our analysis found that the use of anti-TNF or combination therapy at the time of dilation use did not reduce the risk of future surgery after EBD. In fact, the initiation of anti-TNF therapy after dilation increased the risk for future surgery in this retrospective cohort. The conditions where anti-TNF therapy is capable of sufficiently treating stricturing disease are unclear. Anti-TNF initiation in newly diagnosed CD has been shown to reduce future surgery. 16 Furthermore, in the study of adalimumab efficacy in patients with Crohn's disease and symptomatic small bowel strictures (CREOLE), of 97 patients with symptomatic strictures, bowel resection and endoscopic dilation were able to be avoiding after adalimumab initiation in 64% after 24 weeks and 29% after a median follow-up of 4 years. 2 Yet, previous work by our group found that among patients hospitalized for small bowel obstruction due to stricturing CD, anti-TNF use did not reduce the risk of surgery. 17 Although the capacity for anti-TNF therapy to help resolve obstructive disease is apparent, our results suggest that too often disease-modifying therapy is initiated after the therapeutic window has closed. 1 Beyond the retrospective study design, which is a limitation of existing EBD studies, there are several other limitations that should be considered when evaluating the results. Most published EBD studies require patients to either be experiencing obstructive symptoms. Yet, unaccounted variation in provider thresholds to perform initial EBD, subsequent EBD, or surgery is influenced by physician experience, patient acceptance, and surgical candidacy, all of which influence the results. Variation in tolerance for mucosal bleeding and balloon resistance experienced during dilation, and the amount of dilation performed in a single session also varied. Endoscopic technical factors, namely dilation size, while uncontrolled, were the variables we intended to examine. Our measurement of more granular technical details, including stricture location, balloon size, number of balloon stages used during the procedure, time between dilation, and maximum dilation diameter achieved were used to adjust for practice variation.
Another limitation was that a standardized instrument to measure mucosal injury was not used across all reports. There is conflicting evidence as to whether the degree of mucosal injury is associated with either EBD efficacy or safety. 9, 12 Most intestinal strictures contain both moderate-to-severe fibrotic and inflammatory changes, and thus, activity within the stenosis may be unavoidable. 18 We expected to use enterography to objectively assess disease activity at the strictured segment, but only half of patients included underwent imaging in reasonable proximity to their dilation. Finally, we elected not to include ostomy and pouch-related strictures in our analysis, principally because of concern that dilation and surgical decision behavior, and the small sample size from a single center, would skew the results. Previous work has shown that pouch and ostomy-related strictures are responsive to balloon dilation, although studies have been limited to experienced referral centers. 5, 19 In conclusion, EBD of CD-related intestinal strictures is more likely to prevent surgery if a diameter of at least 14 to 15 mm is achieved compared with stopping at smaller dilations, regardless of the ability to pass the endoscope after dilation. Although there was no further reduction in the need for future surgery using larger size dilations, dilations to 16 to 18 mm resulted in a significantly longer interval between maintenance dilations compared with smaller sizes. Anti-TNF therapy was not protective against surgery among those undergoing EBD, likely due to minimal remaining medically responsive intestinal damage. Although we await the advent of antifibrotic medical therapy in CD, we will continue to contend with irreversible CD complications. EBD, in properly selected patients, provides a method to immediately relieve debilitating obstructive symptoms and either avoid or delay surgery. Still, several issues remain surrounding EBD in CD, including the need for better methods to provide a personalized prediction for EBD response and probability of complication. In addition, prospective study of optimal balloon inflation time, frequency of dilations, and number of dilation that can be safely performed at one time in a given stricture are needed. Both enterography-based techniques, as well as novel methods to assess the mechanical properties of intestine including stiffness imaging using magnetic resonance, ultrasound, and photoacoustic imaging, may offer additional insight to guide the technical aspect of EBD in CD. 20 
